Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally.
Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said,
'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.'
Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA.
With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies.
The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US.
Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Why Is Johnson & Johnson (JNJ) Up 7.2% Since Last Earnings Report?
It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 7.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Johnson & Johnson before we dive into how investors and analysts have reacted as of late. Q2 Earnings & Sales Beat Estimates J&J's second-quarter 2025 earnings came in at $2.77 per share, which beat the Zacks Consensus Estimate of $2.66. Earnings, however, declined 1.8% from the year-ago period due to interest associated with incremental debt from the Intra-Cellular acquisition and gross profit erosion from Stelara. Adjusted earnings exclude intangible amortization expense and special items. Including these items, reported earnings were $2.29 per share, up 18.7% year over came in at $23.74 billion, which also beat the Zacks Consensus Estimate of $22.80 rose 5.8% from the year-ago quarter, reflecting an operational increase of 4.6% and a positive currency impact of 1.2%. Organically, excluding the impact of acquisitions/divestitures and currency, sales rose 3.0% on an operational basis. The Stelara loss of exclusivity ('LOE') hurt revenue growth by 710 basis points in the sales in the domestic market rose 7.8% to $13.54 billion. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, domestic sales rose 5.0% in the sales rose 3.2% on a reported basis to $10.2 billion, reflecting an operational increase of 0.6% and a positive currency impact of 2.6%. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, international sales rose 0.4% in the quarter. Segment Details Innovative Medicines Segment J&J's Innovative Medicines segment sales rose 4.9% year over year to $15.2 billion, reflecting a 3.8% operational increase and a positive currency impact of 1.1%. Excluding the impact of all acquisitions and divestitures and currency on an adjusted operational basis, worldwide sales rose 2.4%. Innovative Medicines sales beat the Zacks Consensus Estimate of $14.55 billion as well as our model estimate of $14.50 sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment's growth. Xarelto and Simponi/Simponi Aria sales also rose in the quarter. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. The sales growth was partially dampened by lower sales of Imbruvica and generic/biosimilar competition to drugs like Stelara and Zytiga. Stelara LOE negatively impacted Innovative Medicines segment growth by 1170 basis points. In the Innovative Medicines segment, sales in the United States rose 7.6%, while outside U.S. sales declined 1.6% on an operational Darzalex sales rose 23.0% year over year to $3.54 billion in the quarter, driven by continued share gains across all lines of therapy, particularly the front-line setting, as well as market growth. Sales beat the Zacks Consensus Estimate of $3.45 billion and our model estimate of $3.44 sales declined 4.5% to $735.0 million due to rising competitive pressure in the United States, due to new oral competition and the impact of Medicare Part D redesign. Imbruvica sales were, however, better than the Zacks Consensus Estimate of $697.0 million and our estimate of $694.8 generated sales of $908.0 million in the quarter, up 23.4% year over year, driven by share gains and market growth. Erleada sales beat the Zacks Consensus Estimate of $853.0 million as well as our model estimate of $903.9 drug Carvykti recorded sales of $439.0 million compared with $369 million in the previous quarter, driven by share gains and continued capacity expansion. Another new drug, Tecvayli, recorded sales of $166.0 million in the quarter, up 23.1% year over of Talvey were $106 million, up 55.0% year over year. Tecvayli and Talvey's growth was driven by strong launches in the relapsed-refractory setting. Rybrevant plus Lazcluze sales were $179 million compared with $69 million in the year-ago quarter, driven by a strong launch sales declined 11.6% to $145.0 million in the quarter due to generic competition. ImmunologyStelara sales declined 42.7% to $1.65 billion in the quarter due to the impact of biosimilar competition and Part D redesign. While U.S. sales of Stelara declined 41.9%, international sales declined 44.2% in the quarter. Stelara sales missed the Zacks Consensus Estimate as well as our model estimates of $1.88 biosimilar versions of Stelara have been launched in the United States in 2025. According to patent settlements and license agreements, Amgen, Teva, Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. Stelara biosimilar competition is expected to accelerate throughout 2025 as the number of biosimilar entrants increases. Tremfya recorded sales of $1.19 billion in the quarter, up 31.0% year over year, driven by strong market growth across all indications (including newly launched IBD indications) and overall market growth, partially offset by the impact of Medicare Part D redesign. Tremfya sales beat the Zacks Consensus Estimate of $1.08 billion as well as our model estimate of $1.09 Aria sales rose 28.6% to $690.0 million. Sales of Remicade rose 15.9% in the quarter to $455.0 million. Neuroscience, PH and Other DrugsIn neuroscience, Spravato recorded sales of $414.0 million, up 53.3% year over year, driven by increased physician and patient demand. Caplyta, added from the Apil acquisition of Intra-Cellular Therapies, recorded sales of $211 million in the quarter. Invega Sustenna/Xeplion/Invega Trinza/Trevicta sales declined 5.9% to $992.0 million in the quarter. PH drug Uptravi recorded sales of $476.0 million, up 11.7% year over year. Another PH drug, Opsumit, recorded sales of $582.0 million, up 6.4% year over year. . Xarelto sales rose 5.6% in the quarter to $621.0 million. Prezista sales declined 9.4% to $396.0 million. MedTech Segment MedTech segment sales came in at $8.54 billion, up 7.3% from the year-ago period, including an operational increase of 6.1% and a positive currency impact of 1.2%. MedTech segment sales beat the Zacks Consensus Estimate of $8.25 billion as well as our model estimate of $8.31 the impact of all acquisitions and divestitures, and currency, on an adjusted operational basis, worldwide sales rose 4.1%, driven by strong momentum in Cardiovascular, Surgery and Vision. In the MedTech segment, sales rose 8.0% in the United States and 4.1% outside of the United States on an operational basis. The MedTech business improved from the first-quarter levels, driven by the newly acquired cardiovascular businesses, Abiomed and Shockwave, as well as in Surgical Vision and wound closure in Surgery. Moreover, improvements in J&J's electrophysiology business also drove the sequential the company continues to face headwinds in China. Sales in China were hurt by the impact of the VBP program. Cardiovascular (previously Interventional Solutions) sales grew 23.5%, driven by strong growth in electrophysiology and higher sales of Abiomed and Shockwave. The electrophysiology business improved significantly from the first quarter, driven by electro-anatomical mapping procedure volumes and increased Varipulse ablation catheter adoption and utilization. The electrophysiology business is expected to continue to Surgery rose 2.7% as growth in wound closure and biosurgery offset the impact of competitive pressure in energy and endocutters and VBP issues in China. Worldwide orthopedics declined 0.3% due to competitive pressures, the transformation program and China VBP. Worldwide Vision rose 6.5%, driven primarily by contact lenses as well as almost double-digit growth in Surgical Vision. Ups 2025 Guidance The company raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance coupled with currency sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. Operational sales growth is expected in the range of 4.5% – 5.0% (previously 3.3%-4.3%).Adjusted operational sales (excluding currency impact, acquisitions/divestitures) growth is expected in the range of 3.2%-3.7% (previously 2.0%-3.0%).The revenue figures exclude revenues from COVID-19 vaccine sales. The guidance also does not include the potential impact of the 'Most Favored Nation' 2025, J&J expects growth in the Innovative Medicine segment despite the loss of exclusivity of Stelara, and negative impact of the Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in IBD and Rybrevant in non-small cell lung the MedTech segment, increased adoption of newly launched products in Cardiovascular, Surgery and Vision are likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. While newly launched products should drive better growth in Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90 driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. On an operational, constant-currency basis, adjusted earnings per share are expected to increase in the range of 8.2%-9.2% (previously 5.2% to 7.2%).The guidance range includes tariff costs as well as dilution from the Intra-Cellular Therapies acquisition. In 2025, J&J estimates tariff-related costs of approximately $200 million, lower than the prior estimate of $400 million given on the first-quarter conference call. The tariff costs are exclusively related to its MedTech unit. On an operational, constant-currency basis, adjusted earnings per share are expected to increase in the range of 6.5% – 7.5% (previously 5.2% to 7.2%).Adjusted pretax operating margin is still expected to improve by approximately 300 basis points, driven by cost savings and reduced acquired IPR&D company now projects net interest expense between $0 million and $100 million. Earlier, the company had guided for a net interest expense between $100 million and $200 million. Adjusted tax rate is expected to be approximately 17% to 17.5%. How Have Estimates Been Moving Since Then? In the past month, investors have witnessed a upward trend in estimates review. VGM Scores Currently, Johnson & Johnson has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. Following the exact same course, the stock has a grade of B on the value side, putting it in the top 40% for value investors. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Johnson & Johnson has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
an hour ago
Gas valve failure during routine maintenance work may have led to fatal explosion, US Steel says
HARRISBURG, Pa. -- Preparations for a routine maintenance task may have led to an explosion at a U.S. Steel coal-processing plant near Pittsburgh that left two dead and sent 10 to hospitals, the company said Friday. U.S. Steel said it developed the information, along with other investigators, from reviewing video footage and interviewing employees. That has suggested to them that the explosion happened when workers were flushing a gas valve in preparation for a routine planned maintenance task, the company said. The explosion, which heavily damaged part of the sprawling facility, started around a set of ovens where coal is baked to 1,200 degrees Fahrenheit (648.89 Celsius) into a more efficient carbon fuel called coke, a key component in steelmaking. A byproduct of processing the coal is a combustible gas called coke oven gas, made up of a lethal mix of methane, carbon dioxide and carbon monoxide. 'Pressure built inside the valve, leading to valve failure and coke oven gas filling the area and ultimately exploding when finding an ignition source,' U.S. Steel said. U.S. Steel didn't say why pressure built inside the valve or what was the ignition source. It said the investigation is in the early stages and that it will provide more information when it can. The United Steelworkers union, which represents workers killed and injured in the explosion, had no immediate comment. The massive plant along the Monongahela River in Clairton is considered the largest coking operation in North America and, along with a blast furnace and finishing mill up the river, is one of a handful of integrated steelmaking operations left in the U.S. The blast was so powerful that it sent a plume of black smoke into the sky, shook the ground and was heard by some people a mile or more away. It took hours to find two missing workers, one dead and one alive, beneath charred wreckage and rubble. The Clairton plant is nearly 110 years old. Japan-based Nippon Steel finalized its acquisition of U.S. Steel in June, winning President Donald Trump's approval after he reversed then-President Joe Biden's decision to block it. To change Trump's mind, Nippon Steel boosted its commitment to invest money into U.S. Steel's aging plants and gave the federal government a say over some matters involving domestic steel production.
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
California's third-largest home insurer seeks to hike rates
Mercury Insurance, the third largest home insurer in California, submitted a request for a new rate hike on Friday — the first filing to utilize new state reforms that alter how insurance companies can price for wildfire risk. The filing asks regulators to approve a statewide increase of 6.9%, according to the company. The full details of the filing were not available online as of Friday afternoon. In a statement, Mercury said the increase was necessary to compensate for the insurer's exposure to wildfire risk and inflation that drives up the cost of paying claims. Each homeowners' exact rate change will depend on their wildfires risk — some may see increases that are lower than the average, or even decreases; others' rates will rise above the average. The company said it would also be offering new discounts for wildfire mitigation work, such as installing ember-resistant vents or clearing out brush, which could reduce customers' wildfire portion of their premiums by as much as a third. Mercury is the first company to submit for a rate increase under the Sustainable Insurance Strategy, a package of reforms spearheaded by Insurance Commissioner Ricardo Lara aimed at making insurance more available in California. The reforms allow insurance companies to begin using forward-looking models of wildfire risk to influence premiums and to pass along some of the cost of reinsurance — insurance for insurers — to customers. These reforms were widely expected to lead to rate increases, but also come with a requirement for companies to write more policies in high wildfire-risk areas if they don't do so already. Last year, Mercury confirmed to the Chronicle that it would be among the companies that would be required to write more policies under the new regulations. In anticipation of the reforms being finalized, it announced plans to insure more than 200 homes in Paradise (Butte County), the site of the 2018 Camp Fire. Over the past few years, Los Angeles-based Mercury has scaled up its presence in California's home insurance line, rising from the seventh largest home insurer in 2021 to the third largest in 2024 behind State Farm General and Farmers Insurance Group. Over that same period, Mercury has raised home insurance rates four times — a 6.9% increase in 2021 followed by a 12.6% increase in 2023, a 7% increase in 2024 and another 12% increase that went into effect this March. It's common to see insurance companies request rate hikes of 6.9%. That's because under Proposition 103, the 1988 voter initiative that established California's system for reviewing rate hike requests, consumer groups can request a mandatory hearing for requests of 7% and above. Mercury CEO Gabriel Tirador said in a statement that he believed Lara's reforms would successfully stabilize California's home insurance market. 'Our filing is the first step toward Mercury's goal of expanding insurance options for California homeowners and underscores our 60-year commitment to California customers and agents,' Tirador wrote. 'As other companies scaled back their California operations, Mercury stepped up to provide more options for our agents and customers, and we are committed to continuing our efforts to help protect our California neighbors well into the future.' Its filing makes use of a wildfire catastrophe model made by Verisk, one of three such models recently approved for use by the department. The department will now review whether Mercury's usage of the model reliably supports its request for a 6.9% increase. It's the first of many new filings expected now that wildfire models have been approved for use. Not all companies will be required to write new policies under the regulations — some that already insure a significant number of homes in high-risk areas will only be asked to maintain that presence. But Farmers Insurance Group, California's second largest home insurer, has joined Mercury in writing more new policies to prepare for the reforms. Last year, Allstate Insurance, the eighth largest home insurer as of 2024, signaled it planned to begin writing new policies for the first time since late 2022 once it could begin raising rates under the reforms. It has not set a date for this to happen, however. Officials hope private insurers writing more policies will reverse the rapid growth of the California FAIR Plan, the state's insurer of last resort. 'Our goal is for consumers to have more options to find coverage on their own terms instead of FAIR Plan policies that cover less and cost more,' Deputy Insurance Commissioner Michael Soller said in a statement Friday. 'That will continue to be our top priority.'
